Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task

Guoying Ni; Lu Zhang; Xiaodan Yang; Hejie Li; Bowei Ma; Shelley Walton; Xiaolian Wu; Jianwei Yuan; Tianfang Wang; Xiaosong Liu

doi:10.1080/21645515.2020.1717185

Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task

Hum Vaccin Immunother. 2020 Oct 2;16(10):2328-2332. doi: 10.1080/21645515.2020.1717185. Epub 2020 Mar 11.

Authors

Guoying Ni^{1

2

3}, Lu Zhang¹, Xiaodan Yang¹, Hejie Li^{2

4}, Bowei Ma¹, Shelley Walton², Xiaolian Wu⁵, Jianwei Yuan¹, Tianfang Wang², Xiaosong Liu^{1

2

5

6}

Affiliations

¹ Department of Nuclear Medicine, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University , Guangzhou, China.
² Genecology Research Centre, University of the Sunshine Coast , Maroochydore, Australia.
³ School of Medical Science, Griffith Health Institute, Griffith University , Gold Coast, Australia.
⁴ Institute of Industrial Science, Department of Mechanical and Bio-functional System, The University of Tokyo , Tokyo, Japan.
⁵ Cancer Research Institute, First People's Hospital of Foshan , Foshan, Guangdong, China.
⁶ School of Health and Sport Sciences, University of the Sunshine Coast , Maroochydore, Australia.

Abstract

Interleukin 10 (IL-10) belongs to IL-10 family cytokines that are critical for maintaining the integrity of epithelial tissues, protecting pathogenic infection, and preventing excessive immune responses to damage self. Temporal IL-10 signaling blockade enhances vaccine-induced tumor regression by CD8 + T cells. IL-10, especially pegylated IL-10, mediates tumor regression by expanding tumor-infiltrating CD8 + T cells. Moreover, targeting IL-10 enhances immune checkpoint inhibitor mediated tumor regression. In the current paper, we will review recent advances in this area and discuss the complexity of IL-10 manipulation for cancer therapy.

Keywords: Interleukin 10; PD-1; cancer immunotherapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

CD8-Positive T-Lymphocytes
Cytokines
Humans
Immunotherapy
Interleukin-10*
Interleukin-15
Interleukin-2
Neoplasms* / therapy

Substances

Cytokines
Interleukin-15
Interleukin-2
Interleukin-10

Grants and funding

K07 AG001003/AG/NIA NIH HHS/United States